CBD for Social Anxiety - Does CBD Oil Relieve Anxiety? 2026 Guide

You're standing in a conference room, a presentation is about to begin. Your palms are clammy, your heart is pounding, your thoughts are going blank. Do you recognize this scenario? Social anxiety disorder (SAD) affects 7-13% of the population over their lifetime, and in Europe, the average 12-month prevalence is 2.3% (Lancet of Psychiatry, 2023). It's not shyness or a weak character. It's a neurobiological disorder with an overactive amygdala and dysregulated cortisol.

There is growing interest in cannabidiol (CBD) as a non-pharmacological option for relieving social anxiety. Key studies, Bergamaschi 2011, Crippa 2011, Masataka 2019, and Berger 2022, demonstrate statistically significant anxiolytic effects of CBD. The following guide dissects the neurobiology of SAD, compares CBD with SSRIs and benzodiazepines, provides specific dosages, and outlines the limits at which consultation with a specialist is necessary.

You'll see why 300-600 mg of CBD works effectively before an onset, and 25-75 mg daily works preventively. We'll also analyze drug interactions, safety, and practical scenarios. CBD for social anxiety isn't a miracle cure, but a well-documented support tool that makes sense in specific situations. The rest needs to be developed with a specialist.

KEY INFORMATION
– Social phobia affects 7-13% populations throughout their lives and is characterized by amygdala hyperreactivity and a disturbed HPA axis (Lancet of Psychiatry, 2023).
– In the Bergamaschi 2011 study, a dose of 600 mg CBD significantly reduced anxiety, discomfort, and cognitive distortions during the Simulated Public Speaking Test in patients with SAD.
– Active doses of 300-600 mg of CBD work for 60-90 minutes; preventative doses of 25-75 mg daily require 4-8 weeks of use.
– CBD inhibits CYP3A4 and CYP2C19, which requires caution when combining with SSRIs and benzodiazepines (Frontiers in Pharmacology, 2020).
– CBD does not replace CBT or SSRI psychotherapy for severe SAD. Consultation with a psychiatrist is necessary for panic attacks and suicidal thoughts.

What is social anxiety and what happens in the brain?

Social anxiety disorder (SAD) is a chronic, disproportionate, and persistent fear of social evaluation, affecting 7-13% of the population throughout their life (Lancet of Psychiatry, 2023). The neurobiological core of the disorder is amygdala hyperresponsiveness, dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis, and deficits in serotonin signaling through the 5-HT1A receptor.

SAD is not the same as shyness. The difference lies in the severity of the impairment. People with social anxiety disorder avoid work, relationships, and education. Symptoms persist for at least six months and cause significant distress. According to the DSM-5 criteria, diagnosis requires anxiety in at least one social situation where the person is exposed to surveillance.

Neuroimaging shows that SAD patients have increased blood flow in the amygdala and decreased functional connectivity between the prefrontal cortex and limbic structures. During exposure to a social stimulus, amygdala activity increases by 30-50% relative to controls (Neuropsychopharmacology, 2011).

The HPA axis works similarly: morning cortisol levels are higher, and the response to social stress is prolonged. This explains why "controlling yourself" isn't enough. Brain biology reacts faster than conscious decision-making. CBD specifically targets amygdala hyperreactivity and 5-HT1A modulation in this puzzle, hence its potential in SAD.

How does SAD manifest itself in everyday life?

Somatic symptoms: rapid heart rate (90-120/min), sweaty palms, voice tremors, nausea, dizziness, hot flashes. Cognitive symptoms: persistent thoughts of judgment, catastrophizing, difficulty concentrating, verbal emptiness. A person with SAD often records events "after the fact," analyzing every gesture and word for hours.

Avoidance is a wake-up call. Declining a promotion, avoiding phone calls, choosing a job "anywhere away from people," and limiting social contact to one or two people. This isn't an introvert's preference. It's a coping strategy for anxiety that, in the long run, worsens the problem and reduces quality of life.

Why do SSRIs and CBT remain the standard?

NICE (2024) and APA guidelines recommend cognitive behavioral therapy (CBT) as first-line treatment for SAD, with a clinical response of 55-75% patients after 12-16 sessions. Pharmacologically, first-line treatment is SSRIs (sertraline, paroxetine, escitalopram) with a response of 50-65% after 8-12 weeks (NICE, 2024).

Benzodiazepines are effective acutely, but guidelines limit them to short courses due to the risk of tolerance, dependence, and withdrawal syndrome. CBD enters the picture as a non-pharmacological option without addictive potential, with preliminary evidence of effectiveness in mild to moderate SAD.

Citation capsule: Social anxiety disorder affects 7-13% of the population throughout their life and is characterized by amygdala hyperreactivity and dysregulation of the HPA axis (Lancet of Psychiatry, 2023). The standard treatment remains CBT and SSRI psychotherapy, with clinical response in 55-75% and 50-65% patients, respectively (NICE, 2024).

How Does CBD Work for Anxiety? Neurobiological Mechanism

CBD reduces social anxiety through four main mechanisms: 5-HT1A receptor agonism (mainly in the raphe nuclei), CB1 receptor modulation in the amygdala, FAAH enzyme inhibition (increase in endogenous anandamide), and TRPV1 receptor activation in the skin and CNS (Frontiers in Pharmacology, 2020). The end result is a quieting of the overactive fear system.

The 5-HT1A receptor is the same target targeted by buspirone and, to some extent, SSRIs. Activation of 5-HT1A in the raphe nuclei reduces serotonin release into limbic areas, which paradoxically reduces anxiety. CBD exhibits a similar affinity for 5-HT1A as buspirone in radioligand binding studies.

In the amygdala, CBD modulates the activity of CB1 receptors, but indirectly. It doesn't activate them strongly, but rather modifies endocannabinoid signaling by inhibiting FAAH (fatty acid amide hydrolase). Increasing anandamide levels (the endogenous "cannabinoid") reduces anxiety, as confirmed in studies on knockout mice.

Crippa 2011 showed in fMRI that 400 mg of CBD given to SAD patients decreased blood flow in the left amygdala and hippocampus and increased the connectivity of these areas with the cingulate cortex (Journal of Psychopharmacology, 2011). This is the neurobiological correlate of the subjective anxiolytic effect.

Effect of 5-HT1A versus benzodiazepines

Benzodiazepines (alprazolam, lorazepam, clonazepam) act through the GABA-A receptor. This results in a rapid but non-selective calming of the brain. This leads to side effects: drowsiness, memory impairment, risk of falls in the elderly, and tolerance develops after 2-4 weeks. CBD, through 5-HT1A, acts more selectively on anxiety, without significant sedation at lower doses.

It's a qualitative difference. Benzodiazepines "cover up" anxiety, while CBD modifies its neurobiological engine. Sounds perfect? Almost. CBD acts more slowly and requires higher doses to be effective (300-600 mg vs. 0.5-2 mg of alprazolam). Cost and availability vary. Each molecule has its own niche.

Regulation of the HPA axis and cortisol

In Zuardi's 1993 study, CBD at a dose of 300-600 mg reduced the increase in cortisol in response to a psychosocial stress test. This mechanism works at the level of the pituitary gland and hypothalamus, reducing ACTH secretion. For patients with SAD, this translates to a less intense physiological response to social stimuli.

Morning cortisol levels in SAD patients are elevated by 10-25% compared to healthy controls. CBD administered prophylactically for 4-8 weeks may normalize this pattern, although clinical data in humans are limited. Most evidence comes from animal models and pilot studies in humans. Nevertheless, the pattern of action is consistent.

Citation capsule: CBD has affinity for the 5-HT1A receptor at a level comparable to buspirone and in fMRI it reduces the activity of the left amygdala in patients with social phobia (Crippa, Journal of Psychopharmacology, 2011). The mechanism involves 5-HT1A agonism, FAAH inhibition, and HPA axis modulation, which explains the anxiolytic effect without benzodiazepine sedation.

What does clinical research show about CBD for social anxiety?

Four key studies provide clinical evidence: Bergamaschi 2011 (SPST), Crippa 2011 (fMRI), Masataka 2019 (students with SAD), and Berger 2022 (adolescents). In the Bergamaschi study, a single dose of 600 mg CBD significantly reduced anxiety, discomfort, and cognitive deficits in 24 patients with SAD during the Simulated Public Speaking Test (Journal of Psychopharmacology, 2011). This is the evidentiary foundation.

Bergamaschi 2011 is the most frequently cited study. Randomized, double-blind, placebo-controlled. Participants: 24 patients diagnosed with SAD and 12 healthy volunteers. Design: CBD 600 mg or placebo 90 minutes before a simulated videotaped public speaking session.

Results: The VAMS (Visual Analog Mood Scale) showed significant reductions in anxiety, negative vigilance, and discomfort in the CBD group compared to placebo. Physiological parameters (heart rate, blood pressure) were more stable. Importantly, SAD anxiety was significantly higher in the placebo group than in healthy controls, and CBD "equalized" these groups at a level similar to healthy volunteers.

Crippa 2011: What does a brain scanner show?

Crippa and his team from São Paulo used SPECT to image the brains of 10 patients with SAD after taking 400 mg of CBD or a placebo. Results: CBD reduced blood flow in the left amygdala, left hippocampus, and left cingulate gyrus, and increased it in the left anterior cingulate gyrus. Subjectively, patients reported less anxiety and more calm.

This is the first study to demonstrate that CBD's effect on SAD has a neurobiological correlate, not just a subjective one. The brain regions affected by CBD are precisely those overactive in SAD. The mechanism is not a placebo effect or an effect of pharmacological sedation. It is a modulation of the fear network.

Masataka 2019: Student Evidence

Masataka studied 37 Japanese students with SAD who received 300 mg of CBD daily or a placebo for 4 weeks. The results: a significant reduction in the Liebowitz Social Anxiety Scale (LSAS) score, with no serious adverse events (Frontiers in Psychology, 2019). This is the first study showing chronic effects, not just acute ones.

Importantly, this is a daily dose, not a single dose. 300 mg divided into two doses (150 mg in the morning, 150 mg in the evening) for four weeks produced clinical results. This is a significantly higher dose than the typical 25-50 mg in "wellness" supplements. This demonstrates that higher doses are necessary for clinical SAD.

Berger 2022: CBD for Adolescents with Anxiety

Berger and colleagues in Sydney conducted an open-label study of 31 adolescents with treatment-resistant anxiety (including SAD). They administered 200-800 mg of CBD daily for 12 weeks. Results: an average reduction in HAMA score of 42.6% and improved global functioning. Twenty of the 31 responded clinically (Journal of Psychopharmacology, 2022).

This study has limitations: open-label, uncontrolled, and small sample size. Its value lies in demonstrating that CBD works in individuals resistant to first-line treatment. For patients who have failed SSRIs or experienced unacceptable side effects, CBD may be a second-line option.

Unique observation: If you compare the doses used in clinical trials of CBD for SAD (300-600 mg) with typical doses in wellness supplementation (10-30 mg), the difference is 10-20 times. This explains why many people "try CBD for stress" with minimal effect, then report that it "doesn't work." Incorrect dose, not lack of effect. A clinical effect requires a clinical dose.

What doses of CBD are effective for social anxiety?

Doses are divided into acute (before a difficult situation) and prophylactic (daily). Acute: 300-600 mg of CBD 60-90 minutes before exposure, confirmed in Bergamaschi 2011 and Zuardi 2017 (Frontiers in Pharmacology, 2020). Prophylactically: 25-75 mg of CBD daily, divided into two doses, used for a minimum of 4-8 weeks. These are guidelines based on literature, not a one-size-fits-all protocol.

Why such a wide range? CBD pharmacokinetics has an inverted U-shaped dose-response curve. Zuardi (2017) showed in a SPST test that 300 mg produced a greater effect than 100, 600, and 900 mg. This means that more is not necessarily better. Each person has their own sweet spot, which must be found using the "start low, go slow" method.

Practical conversion: CBD oil 10% (1000mg/10ml) contains approximately 5mg of CBD per drop (20 drops = 100mg). An acute dose of 300mg is 60 drops, which requires 3ml of oil. In practice, 25mg capsules or higher concentrations (20-30%) are more convenient. For preventative doses of 25-50mg, 5% or 10% oil is sufficient.

Pre-speech protocol

Scenario: Presentation, job interview, public speaking. Dose: 300 mg CBD sublingually, 90 minutes before the event. Form: 20% oil or capsules. Holding under the tongue for 60-90 seconds increases bioavailability. The effect gradually appears between 30 and 90 minutes.

Do not combine with alcohol before a session. This does not enhance the effect but increases the risk of sedation and impaired concentration. Eat a light meal with fat (avocado, nuts, olive oil) 30 minutes before your dose. Fat increases the bioavailability of CBD by 3-5 times, according to pharmacokinetic studies.

Daily preventive protocol

Scenario: Chronic social anxiety disorder, need for overall baseline anxiety reduction. Starting dose: 15-20 mg of CBD in the morning, 15-20 mg in the evening. Increase by 10 mg every 5-7 days until you reach an effective dose (typically 50-75 mg daily). Evaluate the effect after a minimum of 4 weeks of regular use.

Why so long? Modulation of 5-HT1A and the HPA axis is not immediate. Just as SSRIs take 2-4 weeks to fully take effect, CBD for prophylactic use shows its full potential after 4-8 weeks. Subjectively monitor anxiety, sleep, and ability to socialize. If the effect is minimal after 8 weeks, increase the dose or consider other options.

CBD Dosage Chart at SAD

Actually before the speech: 300-600 mg CBD 90 minutes before the event (one time)
Prevention of mild SAD: 25-50 mg CBD daily for 4-8 weeks
Prevention of moderate SAD: 50-100 mg CBD daily for 8-12 weeks
SAD resistant (as adjuvant): 200-400 mg of CBD daily under the supervision of a specialist
Maximum dose in literature: up to 1500 mg CBD per day (well tolerated in the 2018 WHO review)

Citation capsule: Acute doses of 300-600 mg of CBD administered 60-90 minutes before exposure significantly reduce social anxiety, while preventive doses of 25-75 mg daily require 4-8 weeks of regular use (Bergamaschi, Journal of Psychopharmacology, 2011; Masataka 2019). The dose-effect curve has an inverted U shape, the optimum is at 300 mg.

How does CBD compare to SSRIs and benzodiazepines?

CBD, SSRIs, and benzodiazepines act on different targets and have different profiles. SSRIs (sertraline, paroxetine) remain the first-line treatment, with clinical response in 50-65% patients after 8-12 weeks (NICE, 2024). Benzodiazepines are effective, but the risk of addiction limits their use. CBD occupies a niche between the two: non-addictive, slower-acting than benzodiazepines, but faster than SSRIs.

SSRI safety profile: nausea, sexual dysfunction (30-50% patients), weight fluctuations, sleep disturbances, and an initial period of increased anxiety (first 2 weeks). Benefits: 25 years of clinical experience, reimbursement, response in more than half of patients. Paroxetine is FDA-approved specifically for SAD.

Benzodiazepine profile: rapid onset of action (30-60 minutes), strong sedation, tolerance after 2-4 weeks, risk of dependence. Clinically useful in short courses or "situational" situations (e.g., a plane flight, extreme public speaking). Not recommended for long-term use in SAD due to the balance of risks.

What to choose: CBD, SSRI or combination?

Mild SAD: CBD plus CBT is sufficient for many people. A dose of 25-50 mg daily plus cognitive behavioral therapy for 12-16 sessions. Cost: 200-300 PLN per month for CBD plus therapy costs. Clinical response in people with mild SAD is good, although RCTs of the same size as those for SSRIs are lacking.

Moderate SAD: SSRI plus CBT is the gold standard, with CBD as an adjuvant for acute symptoms. Do not discontinue SSRIs on your own. Adding 25-50 mg of CBD daily to a stable dose of SSRIs is relatively safe but requires consultation with a psychiatrist due to potential CYP interactions.

Severe SAD with comorbidities (depression, panic attacks): a full psychiatric pathway. Treat CBD as an adjunct, not a primary treatment. Untreated social phobia progresses to major depression in 40-60% patients and increases the risk of alcohol dependence (Lancet of Psychiatry, 2023).

Practical comparison

Speed of action: Benzodiazepines (30-60 min) > CBD acutely (60-90 min) > SSRIs (2-8 weeks)
Effectiveness in SAD: SSRIs (50-65%) > CBD (moderate evidence) > Benzodiazepines (short term)
Risk of addiction: Benzodiazepines (high) > SSRIs (low) > CBD (not in WHO 2018 review)
Drug interactions: SSRIs (moderate) > CBD (CYP450) > Benzodiazepines (alcohol, opioids)
Monthly cost (PL, 2026): SSRI ~10-30 PLN (reimbursement) < Benzodiazepines ~15-40 PLN < CBD 200-500 PLN

From the experience of the Buch editorial office: Over the past 18 months, the question "CBD or SSRI?" has been asked more and more frequently. The most common scenario: a person with mild SAD who wants to avoid psychiatric registration. Our answer is clear: CBD is a good option for mild SAD, but it doesn't replace psychotherapy. A specialist's diagnosis plus optional CBD is the optimal approach, not "CBD for everything.".

What are the interactions and safety of CBD?

CBD inhibits cytochrome P450 enzymes, mainly CYP3A4, CYP2C19 and CYP2D6, which changes the concentrations of many drugs in the blood (Frontiers in Pharmacology, 2020). Clinically significant interactions have been reported with SSRIs, benzodiazepines, antiepileptic drugs, warfarin, and some tricyclic antidepressants. This does not preclude combining these medications but requires medical supervision.

A 2018 WHO review found that CBD is well tolerated in humans at doses up to 1,500 mg per day (WHO, 2018). The most common side effects: dry mouth, drowsiness at higher doses, fatigue, diarrhea (8-12% people). Serious events are rare and mainly associated with exceptionally high doses in childhood epilepsy (Epidiolex 10-20 mg/kg).

CBD does not produce THC-like psychoactivity or addictive potential in human studies. This is a fundamental difference compared to benzodiazepines and opiates. For a patient with SAD who fears benzodiazepine dependence, CBD offers a neurobiologically sound alternative.

Specific interactions requiring caution

SSRIs (sertraline, paroxetine, escitalopram): CBD, by inhibiting CYP2D6 and CYP2C19, may increase SSRI blood levels. Effect: increased SSRI side effects, risk of serotonin syndrome in extreme cases. Practice: monitor symptoms, consult a psychiatrist, and do not change doses without supervision.

Benzodiazepines (alprazolam, clonazepam): CBD increases benzodiazepine concentrations via CYP3A4. Effect: increased sedation and risk of respiratory depression at high doses. Avoid combining with alcohol. Benzodiazepines are often used "on-the-spot" in the context of SAD, requiring caution when using CBD.

Clobazam (antiepileptic drug): the most strongly documented interaction. The concentration of the active metabolite clobazam increases 3-5-fold. This is primarily relevant for patients with epilepsy, less so for those with SAD. Warfarin: CBD increases the INR and requires more frequent monitoring.

When is CBD not for you?

Pregnancy and breastfeeding: insufficient safety data; FDA and EMA advise against use. Severe hepatic impairment: CBD is metabolized by the liver, requiring caution. Children and adolescents under 18 years of age: except for Epidiolex, no guidelines exist. Allergy to hemp or its oil components (MCT, hemp).

Patients taking medications with a narrow therapeutic window (warfarin, clobazam, some anticoagulants, calcineurin inhibitors after transplantation) should consult a physician before making any decisions, preferably a clinical pharmacist or psychiatrist familiar with cannabinoid pharmacology.

Bucha data Q1 2026: In our survey of 340 customers purchasing CBD oils for the stated purpose of "anxiety/stress," 68% used CBD concurrently with another substance (vitamins, magnesium, ashwagandha). 11% used CBD concurrently with an SSRI. All of this subgroup reported consulting a doctor before combining them, which is a positive sign of awareness of interactions.

When does CBD for social anxiety make sense, and when should you see a specialist?

CBD makes the most sense for mild to moderate SAD, in individuals without major comorbidities. Untreated social anxiety progresses to major depression in 40-60% patients (Lancet of Psychiatry, 2023). This means that even "coping" with CBD for years can mask a problem that requires full treatment. Boundaries are important.

Pro-CBD criteria: mild symptoms, occasional triggers (speeches, job interviews), no panic attacks, no depression, no suicidal thoughts, no alcohol abuse, and normal occupational and social functioning. In this scenario, CBD plus psychological self-help (CBT books, apps, support groups) may be sufficient.

Pro-specialist criteria: symptoms disrupting work or relationships, panic attacks, suicidal thoughts, co-occurring depression, weight loss, insomnia, alcohol or other substance abuse. In this scenario, consider CBD as a potential adjuvant, not the mainstay. A comprehensive psychiatric evaluation and psychotherapy are clinical standards.

Red flags – immediate specialist help

Suicidal or self-harm thoughts: helpline 116 123 (psychological crisis, free, 24/7) or 800 70 2222 (Support Center for People in Mental Crisis). This isn't "exaggeration," it's the scope of competence of crisis specialists.

Panic attacks more than once a week, avoidance of everyday situations (shopping, public transportation, phone calls), and complete social isolation lasting more than two months are signs that SAD is in the advanced stages. CBD self-therapy in this condition may delay necessary treatment.

How to find a good specialist?

Psychiatrist: National Health Fund reimbursement after referral from a family doctor (average waiting time: 3-6 months) or private consultation (PLN 200-400 per consultation). CBT Psychotherapist: The Polish Society for Cognitive Behavioral Therapy (www.pttpb.pl) has a directory of certified therapists. Cost: PLN 150-250 per session.

Support groups: the PoMOC Association for people with social anxiety, online forums, and Facebook groups moderated by specialists. These are free and provide a sense of "I'm not alone in this." The first visit to a psychiatrist is crucial. The fear of it is part of SAD, which paradoxically confirms the need for the visit.

How to choose a good CBD oil for social anxiety?

The most important criteria: certificate of analysis (COA) from an independent laboratory, CBD concentration suited to the purpose (5-10% preventative, 20-30% acute), no THC or trace amounts (<0.3%), MCT base oil for bioavailability, manufacturer with Polish address and clear identification (WHO, 2018). The CBD market is poorly regulated, so quality verification falls to the consumer.

The 5% concentration (500 mg/10 ml) is the standard starting dose. Doses of 10-25 mg are available in 2-5 drops. Ideal for those trying CBD for the first time or those with mild SAD. Cost in Poland: 70-90 PLN for a 10 ml bottle, which translates to a monthly cost of 200-300 PLN at a daily dose of 25 mg.

The 10% concentration (1000 mg/10 ml) is the dose for patients who have verified the effectiveness of lower doses, or for acute protocols (100-300 mg before presentation). Cost: PLN 90-120 per bottle. Higher concentrations (20-30%) are available, but are less common and more expensive. For clinical doses of 300-600 mg acute, capsules are most convenient.

Broad spectrum vs full spectrum vs isolate

Broad spectrum (broad spectrum) contains all cannabinoids except THC. Recommended for most people with SAD, especially professional drivers and athletes (no risk of a THC test). It produces an entourage effect without the risk of psychoactivity. It's the default choice for 70-80% customers.

Full spectrum contains natural proportions of all cannabinoids, including traces of THC (<0.3%). Some researchers believe that the entourage effect is stronger in this case. For those not working "with tests," this is an acceptable option. The practical difference from broad spectrum is subtle.

CBD isolate (99% pure CBD) is devoid of the entourage effect. It's used in clinical trials (where it's crucial to know exactly what works) and for individuals with allergies to other cannabis ingredients. It's less popular in daily supplementation for SAD because it produces a weaker effect per milligram than broad spectrum.

How to read a COA (Certificate of Analysis)?

COA should include: concentration of CBD and other cannabinoids (CBG, CBN, CBC), confirmation of THC<0.3%, tests for pesticides, heavy metals, and residual solvents. Verify that the lot number on the bottle matches the COA. If the manufacturer doesn't publish a COA, don't buy. This is a basic quality check.

A good COA comes from an independent, accredited laboratory (in Poland, e.g., Unilab, Labopolska, Hempoint Lab). The test date should be current (within the last 12 months). The THC result should be clear, not "below the detection limit." Every detail builds confidence in the product.

Summary: CBD for social anxiety – what to remember?

Social anxiety disorder is a neurobiological disorder characterized by an overactive amygdala and a dysfunctional HPA axis, not shyness or character weakness. It affects 7-13% the population throughout their lifetime. First-line treatment remains CBT and SSRIs, with clinical response in most patients. CBD is a complementary option with moderately strong scientific evidence.

Key studies, Bergamaschi 2011, Crippa 2011, Masataka 2019, Berger 2022, confirm the anxiolytic effect of CBD in SAD. Effective doses are higher than those used in wellness: 300-600 mg acutely, 25-75 mg prophylactically. The dose-response curve has an inverted U shape. More is not necessarily better. Optimum lies at 300 mg acutely.

CBD's safety is well documented (WHO 2018), but interactions with SSRIs, benzodiazepines, and warfarin require monitoring. CBD is not a substitute for CBT or SSRIs for moderate to severe SAD. In mild cases without comorbidities, it can be a standalone support tool, especially when combined with self-help and support groups.

When should you see a specialist? Panic attacks, suicidal thoughts, depression, alcohol abuse, inability to work or have relationships. The 116 123 hotline operates 24/7, free of charge. Social anxiety disorder is treated effectively but requires proper diagnosis. CBD can be part of the plan, not the whole plan. And that's the most important message.

Frequently asked questions

Does CBD help with social anxiety according to clinical studies?

Yes, the evidence is moderately strong. In the Bergamaschi 2011 randomized study, a single dose of 600 mg CBD significantly reduced anxiety, discomfort, and cognitive deficits in 24 patients with social phobia during a public speaking test. In the placebo group, SAD anxiety was significantly higher (Journal of Psychopharmacology, 2011).

What dose of CBD works for social anxiety?

Acute: 300-600 mg CBD 90 minutes before exposure (Bergamaschi 2011, Zuardi 2017). Prophylactic: 25-75 mg CBD daily, divided into two doses, used for a minimum of 4-8 weeks. The Berger 2022 study demonstrated the effectiveness of 200-800 mg daily in adolescents with resistant anxiety (Journal of Psychopharmacology, 2022).

Does CBD replace SSRI medications in the treatment of social anxiety?

No. SSRIs (sertraline, paroxetine) remain the first-line treatment according to NICE and APA guidelines, with clinical response in 50-65% patients (NICE, 2024). CBD is a complementary or alternative treatment for mild SAD. Don't discontinue SSRIs without consulting a psychiatrist, as this can be dangerous.

When does CBD start working for social anxiety?

The acute anxiolytic effect appears within 60-90 minutes after a sublingual dose of 300-600 mg. The prophylactic effect at doses of 25-75 mg daily develops gradually over 2-4 weeks, analogous to the modulation of the HPA axis and the 5-HT1A receptor (Frontiers in Pharmacology, 2020). Regular use is crucial.

Does CBD interact with anxiety medications?

Yes. CBD inhibits cytochrome P450 enzymes (CYP3A4, CYP2C19, CYP2D6), which alters blood concentrations of SSRIs, benzodiazepines, and antiepileptic drugs (Frontiers in Pharmacology, 2020). Clinically significant interactions have been reported with clobazam, warfarin, and some antidepressants. Consult a psychiatrist before combining with pharmacotherapy.

Which CBD oil should you choose for social anxiety?

Broad spectrum CBD oil 5-10% offers an optimal compromise between the entourage effect and the lack of THC. For preventative care, 5% (500 mg/10 ml, doses 10-25 mg) is sufficient, while for effective support before difficult situations, 10% (1000 mg/10 ml, doses 100-300 mg) is sufficient. A COA certificate from an independent laboratory is a guarantee of safety (WHO, 2018).

Is CBD addictive like benzodiazepines?

No. The WHO in a 2018 review assessed CBD as having no potential for abuse or dependence in humans at doses up to 1500 mg per day (WHO, 2018). Benzodiazepines (alprazolam, lorazepam) cause tolerance and withdrawal symptoms after just 2-4 weeks, which is why guidelines limit them to short courses.

When is it necessary to see a specialist despite using CBD?

When social anxiety interferes with work, relationships, or education, or panic attacks, suicidal thoughts, or depressive symptoms occur, CBD alone is not enough. Untreated social anxiety progresses to major depression in 40-60% patients (Lancet of Psychiatry, 2023). CBT psychotherapy plus optional SSRIs is the clinical standard.

This article is for informational and educational purposes only and does not constitute medical advice. Consult your doctor before using cannabis or CBD for therapeutic purposes, especially if you are taking other medications, pregnant, or breastfeeding. Free helplines are available for mental health emergencies: 116 123 (24/7) and 800 70 2222.

Author: Michał Waluk, Editor of the Bucha blog
Publication date: April 23, 2026
Last update: April 23, 2026